: Patients with chronic lymphocytic leukemia (CLL) progressing on ibrutinib constitute an unmet clinical need. Though BTK and PLCG2 mutations are associated with ibrutinib resistance, their frequency and relevance to progression are not fully understood. In this multicenter retrospective observational study, we analyzed 98 patients with CLL treated with ibrutinib (49 relapsing after an initial response and 49 still responding after ≥1 year of continuous treatment) using a next-generation sequencing (NGS) panel (1% sensitivity) comprising 13 CLL-relevant genes including BTK and PLCG2. BTK hotspot mutations were validated by droplet digital PCR (ddPCR) (0.1% sensitivity). By integrating NGS and ddPCR results, 32/49 relapsing cases (65%) carried at least 1 hotspot BTK mutation and/or PLCG2 mutation(s); in 6/32, BTK mutations were only detected by ddPCR [variant allele frequency (VAF) 0.1-1.2%]. BTK/PLCG2 mutations were also identified in 6/49 responding patients (12%; 5/6 VAF <10%), of whom 2 progressed at later time points. Among the relapsing patients, the BTK-mutated (BTKmut) group was enriched for EGR2 mutations, while BTK-wildtype (BTKwt) cases more frequently displayed BIRC3 and NFKBIE mutations. Using an extended capture-based panel, only BRAF and IKZF3 mutations showed a predominance in relapsing cases, who were enriched for del(8p) (n=11; 3 BTKwt). Finally, no difference in TP53 mutation burden was observed between BTKmut versus BTKwt relapsing cases, and ibrutinib treatment did not appear to favor selection of TP53-aberrant clones. In conclusion, we show that BTK/PLCG2 mutations were absent in a substantial fraction (35%) of a real-world cohort failing ibrutinib, and propose additional mechanisms contributing to resistance.

BTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib

Bonello, Lisa;Coscia, Marta;
2023-01-01

Abstract

: Patients with chronic lymphocytic leukemia (CLL) progressing on ibrutinib constitute an unmet clinical need. Though BTK and PLCG2 mutations are associated with ibrutinib resistance, their frequency and relevance to progression are not fully understood. In this multicenter retrospective observational study, we analyzed 98 patients with CLL treated with ibrutinib (49 relapsing after an initial response and 49 still responding after ≥1 year of continuous treatment) using a next-generation sequencing (NGS) panel (1% sensitivity) comprising 13 CLL-relevant genes including BTK and PLCG2. BTK hotspot mutations were validated by droplet digital PCR (ddPCR) (0.1% sensitivity). By integrating NGS and ddPCR results, 32/49 relapsing cases (65%) carried at least 1 hotspot BTK mutation and/or PLCG2 mutation(s); in 6/32, BTK mutations were only detected by ddPCR [variant allele frequency (VAF) 0.1-1.2%]. BTK/PLCG2 mutations were also identified in 6/49 responding patients (12%; 5/6 VAF <10%), of whom 2 progressed at later time points. Among the relapsing patients, the BTK-mutated (BTKmut) group was enriched for EGR2 mutations, while BTK-wildtype (BTKwt) cases more frequently displayed BIRC3 and NFKBIE mutations. Using an extended capture-based panel, only BRAF and IKZF3 mutations showed a predominance in relapsing cases, who were enriched for del(8p) (n=11; 3 BTKwt). Finally, no difference in TP53 mutation burden was observed between BTKmut versus BTKwt relapsing cases, and ibrutinib treatment did not appear to favor selection of TP53-aberrant clones. In conclusion, we show that BTK/PLCG2 mutations were absent in a substantial fraction (35%) of a real-world cohort failing ibrutinib, and propose additional mechanisms contributing to resistance.
2023
1
35
Bonfiglio, Silvia; Sutton, Lesley-Ann; Ljungström, Viktor; Capasso, Antonella; Pandzic, Tatjana; Weström, Simone; Foroughi-Asl, Hassan; Skaftason, Aron; Gellerbring, Anna; Lyander, Anna; Gandini, Francesca; Gaidano, Gianluca; Trentin, Livio; Bonello, Lisa; Reda, Gianluigi; Bödör, Csaba; Stavroyianni, Niki; Tam, Constantine S; Marasca, Roberto; Forconi, Francesco; Panayiotidis, Panayiotis; Ringshausen, Ingo; Jaksic, Ozren; Frustaci, Anna Maria; Iyengar, Sunil; Coscia, Marta; Mulligan, Stephen P; Ysebaert, Loïc; Strugov, Vladimir; Pavlovsky, Carolina; Walewska, Renata; Österborg, Anders; Cortese, Diego; Ranghetti, Pamela; Baliakas, Panagiotis; Stamatopoulos, Kostas; Scarfò, Lydia; Rosenquist, Richard; Ghia, Paolo
File in questo prodotto:
File Dimensione Formato  
Bonfiglio et al Blood Adv 2023.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 1.02 MB
Formato Adobe PDF
1.02 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1888045
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact